Xeris Biopharma Holdings, Inc.
XERS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867096
In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 9 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Xeris Biopharma Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 9 filings
- 3 insiders, $1.85M in total
- Insiders trading
- 3
- Net value
- −$1.85M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Xeris Biopharma Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| McCulloch Kevin | See Remarks | 1,639,208 | Sep 1, 2026 | 8 |
| Hecht Beth | See Remarks | 1,127,796 | Sep 1, 2026 | 11 |
| Pieper Steven | See Remarks | 1,356,053 | Sep 1, 2026 | 5 |
| Shannon John Patrick Jr | See Remarks | 2,898,933 | Aug 21, 2026 | 4 |
| Kreher Nerissa | Director | 33,582 | Jul 2, 2026 | 1 |
| Persky Marla | Director | 150,693 | Jun 5, 2026 | 1 |
| Johnson John | Director | 707,276 | Jun 5, 2026 | 2 |
| Kong Garheng | Director | 238,337 | Jun 5, 2026 | 1 |
| Bormann-Kennedy Barbara-Jean Anne | Director | 150,693 | Jun 5, 2026 | 2 |
| Halkuff Dawn | Director | 119,193 | Jun 5, 2026 | 1 |
| Brady James Aloysius | Director | 113,359 | Jun 5, 2026 | 2 |
| Nguyen Anh Tu | See Remarks | 395,023 | Feb 25, 2026 | 2 |
| Sherman Jeffrey W | Director | 219,188 | Aug 29, 2025 | 0 |
| Johnson Kenneth Erland | See Remarks | 320,446 | Feb 3, 2025 | 0 |
| Schmid John P. | Director | 25,200Indirect | Aug 13, 2024 | 0 |
| Fairley Ricki Louise | Director | 135,000 | Jun 5, 2024 | 0 |
| Edick Paul R | See Remarks | 3,788,064 | Jan 31, 2024 | 0 |
| Prestrelski Steven | Chief Scientific Officer | 719,780 | Feb 1, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 (view filing)6:21 PM ET | Sep 1 | Same day | McCulloch KevinSee Remarks | SSale | −15.0K | $8.49 | −$127.3K | −0.9%1.64M after | 10b5-1 |